Start exploring your own markets for free

🚀 Try for Free

AI Therapeutics

Light Search completed
Invite
Radar Tracking

Subspaces (4)

Drug Discovery Optimization
Biomarker Identification
Genomic Data Analysis
Drug Repurposing

Pending to review

Not sure yet

Interested

Not interested

Download list

Showing 104 results
Company
Fit assessment
Description
Subspaces
Tags
HQ Location
Founding Date
Employees
Total Funding Raised
Last Funding Event
Received on
Biovista

Biovista effectively leverages machine learning for drug repositioning, pattern discovery, and expanding therapeutic options, making it a strong fit for the specified requirements.

Developer of an artificial intelligence-based biotechnology platform intended to deliver custom drug repositioning, drug de-risking, and clinical hold services for the biopharma industry. The company's platform offers systematic discovery services based on proprietary technology and a unit that finds novel uses for drugs and profiles and their side effects using mechanism-of-action analytics, enabling medical professionals to find cures for oncology, auto-immune, and other rare diseases.
  • Drug Repurposing
Light Search
United States199911 - 50NA
Oct 14, 2024
Atomwise

Atomwise is a preclinical pharmaceutical company that utilizes artificial intelligence to enhance the drug discovery process. Their proprietary technology, AtomNet®, focuses on identifying and optimizing small-molecule drug candidates for various disease targets.

Operator of an artificial intelligence-based biotechnology company intended to help invent new potential medicines for disease targets. The company's technology helps in drug hit discovery, binding affinity prediction, and toxicity detection, enabling scientists to discover small molecules for the treatment and investigation of human diseases.
  • Drug Discovery Optimization
Light Search
San Francisco (United States)201251 - 200$176.65MGrant, $2.30M, October 6, 2020
Oct 14, 2024
BenevolentAI

BenevolentAI is a clinical-stage company that utilizes an AI platform to enhance drug discovery and development. It focuses on generating novel drug candidates with a higher likelihood of success through advanced data analysis and scientific collaboration.

Benevolent AI is a clinical-stage AI-enabled drug discovery company. It delivers novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform powers a growing in-house pipeline of over 20 drug programmes, spanning from target discovery to clinical studies, and it maintains commercial collaborations with pharmaceutical companies.
  • Drug Discovery Optimization
Light Search
London (United Kingdom)2013201 - 500$1.90BIPO, $1.61B, April 25, 2022
Oct 14, 2024
Zymergen

Ginkgo Bioworks is a biotechnology company that specializes in designing and engineering custom microbes for various applications, including pharmaceuticals. They focus on developing innovative biological products and optimizing processes for a range of industries, including therapeutics and vaccines.

  • Drug Repurposing
Light Search
Emeryville (United States)$172.14MSeries B, $130.00M, October 11, 2016
Oct 14, 2024
NuMedii

NuMedii effectively leverages machine learning and AI to discover new patterns, expand therapeutic options, and identify potential drug repurposing opportunities.

Operator of a biotechnology company intended to address unmet medical needs. The company identifies compounds that modulate diverse networks involved in diseases and can help with myriad aspects of drug discovery including identifying patient subgroups, new therapeutic options and biomarkers, enabling researchers to harness big data and artificial intelligence to rapidly discover connections between drugs and diseases at a systems level.
  • Drug Repurposing
Light Search
United States20081 - 10$5.50MSeries A, $2.00M, August 17, 2015
Oct 14, 2024
Exscientia

Exscientia utilizes artificial intelligence and big data to enhance the process of drug discovery and development, focusing on designing and optimizing new drug candidates. Their platform has successfully delivered AI-designed drugs that have entered clinical trials, significantly improving productivity in the pharmaceutical industry.

Exscientia is a global pharmatech company using patient-first artificial intelligence (AI) to discover better drugs, faster. Our mission is to encode, automate and transform every stage of the drug design and development process, by combining the latest AI techniques with experimental innovation, to enable the design of patient centric drug candidates with an improved probability of success. Our validated platform has delivered the first three AI-designed drugs to enter clinical trials and is the first AI system proven to improve clinical outcomes in oncology. We’ve significantly accelerated pre-clinical drug discovery, with 10x productivity improvement in delivering a drug candidate compared with industry standards. By actively applying AI to precision engineer medicines more rapidly and efficiently, we allow the best ideas of science to rapidly become the best medicines for patients.
  • Drug Discovery Optimization
Light Search
Oxford (United Kingdom)2012201 - 500$3.67BAcquired by Recursion Pharmaceuticals, August 2024
Oct 14, 2024
BostonGene

BostonGene Corporation develops advanced biomedical software that utilizes AI for personalized therapy decision-making in cancer treatment, focusing on individual patient profiles and tumor characteristics. Their solutions include comprehensive molecular and immune profiling to optimize treatment options for patients.

Developer of biomedical software designed for advanced patient analysis and personalized therapy. The company's platform performs analytics for each patient's genetics, tumor, and tumor microenvironment, clinical characteristics, and disease profile, providing clinicians with aid in their evaluation of viable treatment options.
  • Drug Repurposing
Light Search
United States2015501 - 1000$200.00MSeries B, $150.00M, April 6, 2022
Oct 14, 2024
Lantern Pharma (NAS: LTRN)

Lantern Pharma, Inc. is a clinical stage pharmaceutical company focused on developing precision cancer drugs and revitalizing abandoned cancer therapies. They utilize advanced AI and machine learning techniques to enhance drug discovery and patient stratification in oncology.

Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
  • Drug Repurposing
Light Search
United States201311 - 50$188.24MVenture - Series Unknown, $60.00M, January 14, 2021
Oct 14, 2024
Archetype Therapeutics

Archetype effectively utilizes machine learning for drug discovery, pattern discovery in patient data, and has a proven track record in expanding therapeutics through drug repurposing.

Operator of a drug discovery platform intended to leverage artificial intelligence for patient-specific medicine. The company offers a new approach to drug discovery using AI and patient data to build computer models that identify promising drug candidates, enabling customers to screen billions of molecules to find the effective treatments and improve patient outcomes.
  • Drug Discovery Optimization
  • Drug Repurposing
Light Search
United States20221 - 10NA
Oct 14, 2024
Catenion

Catenion effectively leverages machine learning and data science to discover patterns and expand therapeutic opportunities, including drug repurposing.

Operator of a management consulting firm intended to create effective strategies and optimize business resources for growth and development of pharmaceutical companies. The company's management consulting services include strategy and portfolio management, asset valuation, risk assessment and offering education programmes on decision analysis, enabling pharmaceutical and medical products companies to assess the value and risk of their projects and product portfolios, increase returns on R&D and marketing investments, improve the performance of the organization and allocate resources optimally.
  • Genomic Data Analysis
  • Drug Repurposing
Light Search
Germany200311 - 50NA
Oct 14, 2024